@the_news_21
Government has cleared two vaccines Covishield and Covaxin for emergency use in India, however, people are worried about the pricing of vaccines. Serum Institute of India’s CEO Adar Poonawalla stated that if the government allows sale in the retail, the vaccine will be commercially available at ₹ 1,000 per dose, reported NDTV.
India’s drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
The Drugs Controller General of India (DCGI) granted approval on the basis of recommendations by a COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
This clears the way for the roll-out of at least two vaccines in India in the coming days.
Serum and Bharat Biotech vaccines have to be administered in two doses and these vaccines have to be stored at 2-8° C.
The Serum Institute of India, the world’s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield, while Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
